



Approved for use through 07/31/2006. GMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/534651
				Filing Date	May 12, 2005
				First Named Inventor	Rodney Brian Hargreaves
				Art Unit	1615
				Examiner Name	Not Yet Assigned
Sheet	1	of	4	Attorney Docket Number	ASZD-P01-898

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.*	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
RRM 2-23-07	AA*	US-6,613,942	09-02-2003	Ling et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.*	Foreign Patent Document Country Code ³ -Number-Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
RRM	BA	WO-00/026202-A1	05-11-2000	Pharmacia & Upjohn S.P.A.	
	BB	WO-00/58293-A1	10-05-2000	F. Hoffmann-La Roche AG	
	BC	WO-01/20327-A1	03-22-2001	AstraZeneca AB	
	BD	WO-01/44218-A1	08-21-2001	F. Hoffmann-La Roche AG	
	BE	WO-01/83465-A2	11-08-2001	F. Hoffmann-La Roche AG	
	BF	WO-01/63478-A2	11-08-2001	F. Hoffmann-La Roche AG	
	BG	WO-01/85706-A1	11-15-2001	F. Hoffmann-La Roche AG	
	BH	WO-01/85707-A1	11-15-2001	F. Hoffmann-La Roche AG	
	BI	WO-02/00633-A1	01-03-2002	Tularik Inc.	
	BJ	WO-02/024682-A1	03-28-2002	Janssen Pharmaceutica N.V.	
	BK	WO-02/064545-A1	08-22-2002	Aventis Pharma Deutschland GMBH	
	BL	WO-02/08209-A1	01-31-2002	F. Hoffmann-La Roche AG	
	BM	WO-02/14312-A1	02-21-2002	F. Hoffmann-La Roche AG	
	BN	WO-02/46173-A1	08-13-2002	F. Hoffmann-La Roche AG	
	BO	WO-02/48108-A2	08-20-2002	F. Hoffmann-La Roche AG	
	BP	WO-03/000262-A1	01-03-2003	AstraZeneca AB	
	BQ	WO-03/000267-A1	01-03-2003	AstraZeneca AB	
	BR	WO-03/015774-A1	02-27-2003	AstraZeneca AB	
	BS	WO-03/022856-A1	03-20-2003	Pharmacia & Upjohn Company	
	BT	WO-03/028641-A2	04-10-2003	Taisho Pharmaceutical Co., Ltd.	
	BU	WO-03/047626-A1	06-12-2003	Novo Nordisk A/S	
	BV	WO-03/048152-A2	06-12-2003	Tularik Inc.	
	BW	WO-03/055482-A1	07-10-2003	Novo Nordisk A/S	
	BX	WO-03/080585-A1	10-02-2003	Banyu Pharmaceutical Co., Ltd.	
	BY	WO-03/082838-A1	10-09-2003	Shanghai Institute of Materia Medica	
	BZ	WO-03/095438-A1	11-20-2003	F. Hoffmann-La Roche AG	
	BA1	WO-03/097824-A1	11-27-2003	Banyu Pharmaceutical Co., Ltd.	
	BB1	WO-04/002481-A1	01-08-2004	Novo Nordisk A/S	
	BC1	WO-04/045614-A1	06-03-2004	AstraZeneca AB	
	BD1	WO-04/046139-A1	08-03-2004	AstraZeneca AB	
	BE1	WO-04/050645-A1	08-17-2004	Novartis AG	
	BF1	WO-04/052869-A1	08-24-2004	F. Hoffmann-La Roche AG	
	BG1	WO-04/063179-A1	07-29-2004	Eli Lilly and Company	
	BH1	WO-04/063194-A1	07-29-2004	Eli Lilly and Company	

Examiner Signature	RRM	Date Considered	3/17/2004
--------------------	-----	-----------------	-----------